Lupus & antiphospholipid syndrome
Bifidobacterium ameliorates lupus nephritis and modulates aberrant differentiation of lymphocyte subsets
Authors' conclusion
Bifidobacterium is significantly diminished in SLE patients, influencing kidney injury and immune cell balance in LN. Moreover, Bifidobacterium, its total metabolites and SCFAs' supplementation in MRL/lpr mice notably improved kidney damage and restored immune cell equilibrium in MRL/lpr mice.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients (clinical samples) and MRL/lpr mice
- Participants
- 61 SLE patients
- Comparison
- Bifidobacterium, its total metabolites and short-chain fatty acids (SCFAs) supplementation in MRL/lpr mice; SLE patients' gut microbiota and lymphocyte subsets
Methodological detailsclinical samples and MRL/lpr mouse model, flow cytometry, 16S rRNA sequencing
- Clinical samples and MRL/lpr mouse model
- Flow cytometry
- 16S rRNA sequencing
Main finding
As reported in the abstract
- SLE patients: decreased gut microbiota abundance and diversity, particularly a reduction in Bifidobacterium
- Lupus nephritis (LN) patients: lower proportions of memory B cells, central memory T cells, Treg cells and IL-2; increased effector memory T cells, Th1 and Th17 cells, IL-10 and IFN-γ
- Mice: Bifidobacterium, its metabolites and SCFAs corrected CD4+ T- and B-cell subset and cytokine imbalances, reduced autoantibodies and alleviated kidney damage
Original publication
Bifidobacterium ameliorates lupus nephritis and modulates aberrant differentiation of lymphocyte subsets. Rheumatology (Oxford). Published 24 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →